Skip to main content

Advertisement

Figure 5 | Stem Cell Research & Therapy

Figure 5

From: A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus

Figure 5

The immunologic tests and markers of systemic inflammation. A: The changes in the numbers of CD3+, CD4+ and CD8+ T lymphocytes between baseline and six months. B: Changes in the serum levels of IL-6, IL-10, IL-1β and TNF-α between baseline and six months. The results are shown as the mean ± S.D. *P <0.05 compared with pretreatment. The analysis included 22 patients before and six months after umbilical cord mesenchymal stem cell transplantation.

Back to article page